Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products > Novel inhibitors

Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCC2066 Fak Degrader Fc-11
Novel highly potent FAK-targeting PROTAC degrader, showing a rapid and reversible FAK degradation
More description
DCC2065 Fak Blocker A18
Novel blocker of focal adhesion kinase (FAK) autophosphorylation
More description
DCC2064 Fai-40
Novel inhibitor of fungal fatty acid biosynthesis, demonstrating broad-spectrum activity against Candida auris and mucormycetes and retained the activity against azole-resistant candida isolates
More description
DCC2063 Fa-hp-ß-cyd
Novel folate-appended 2-hydroxypropyl-ß-cyclodextrin (HP-ß-CyD), showing strong anti-leukemia and cell-binding activities, inhibiting the growth of FR-expressing cells, enterjng CML cells through endocytosis and inducing both apoptosis and autophagy via m
More description
DCC2062 Fa-gflg-sn38
Novel Folate Receptor Targeting and Cathepsin B-Sensitive Drug Delivery System for Selective Cancer Cell Death and Imaging, exhibited strong cytotoxicity against FR-overexpressing SK-Hep-1, HeLa, and Siha cells, with IC50 values of 2-3 μM, but had no effe
More description
DCC2061 Fagaronine Chloride
Novel antileukaemic alkaloid; Inhibitor of reverse transcriptase activity of RNA-tumor viruses; Inhibitor of topoisomerase I
More description
DCC2060 Factor Viia Inhibitor 2
Novel factor VIIa inhibitor
More description
DCC2059 Factor Viia Inhibitor 1
Novel factor VIIa inhibitor
More description
DCC2058 Fabp4/5-in-b8
Novel dual inhibitor of fatty acid binding protein 4 (FABP4) and fatty acid binding protein 5 (FABP5)
More description
DCC2057 Fabp4/5-in-a16
Novel dual inhibitor of fatty acid binding protein 4 (FABP4) and fatty acid binding protein 5 (FABP5)
More description
DCC2056 Fabp4/5-in-3
Novel FABP4/5 inhibitor, inhibiting lipolysis in 3T3-L1 adipocytes and in primary human adipocytes, reducing plasma triglyceride and free fatty acid levels, ameliorating dyslipidemia but not insulin resistance in mice with diet-induced obesity
More description
DCC2055 Fabh-in-44
Novel inhibitor of β-ketoacyl-(acyl-carrier-protein) synthase III (FabH).
More description
DCC2054 Fabh Inhibitor 10
Novel FabH Inhibitor, showing potent antibacterial activity with a MIC value of 3.89–7.81 μM−1 against the tested bacterial strains and exhibiting potent E. coli FabH inhibitory activity with an IC 50 value of 1.6 μM
More description
DCC2053 Fa-alkyne
Novel clickable fumarate-competitive chemoproteomic probe
More description
DCC2052 Fa-613
Novel pyrimidine synthesis inhibitor, exhibiting low micromolar antiviral activity against various influenza A and B virus strains, including the highly pathogenic influenza A strains H5N1 and H7N9, enterovirus A71, respiratory syncytial virus, human rhin
More description
DCC2051 F81-1144b
Novel matrix metalloproteinase inhibitor, reducing secretion of very low density lipoprotein-triacylglycerol, lowering TAG levels in serum and the liver, VLDL-TAG secretion, de novo FA synthesis in the liver, and serum levels of insulin and glucose
More description
DCC2050 F2209-0381
Novel and potent inhibitor of PCAF catalytic domain
More description
DCC2049 F-15741
Selective, potent inhibitor of the late current mediated by the cardiac isoform of the sodium channel (NaV1.5)
More description
DCC2048 F1414-1444
Novel bactericidal, killing Mycobacterium tuberculosis by targeting iron-sulfur protein Rv0338c (IspQ), a putative redox sensor
More description
DCC2047 F1414-1438
Novel bactericidal, killing Mycobacterium tuberculosis by targeting iron-sulfur protein Rv0338c (IspQ), a putative redox sensor
More description
DCC2046 F1386-0303
Novel potent and selective MAP4K4 inhibitor
More description
DCC2045 F0371-0041
Novel antifungal agent against Candida albicans persister cells
More description
DCC2044 F0045(s)
Novel influenza A hemagglutinin (HA) fusion inhibitor (EC 50 = 1.9 ± 0.3 μM), preventing HA from transitioning to the postfusion state at pH 5.0
More description
DCC2043 Ezn-2208
Polyethylene glycol conjugate of SN38, acting as a topoisomerase I inhibitor,, exerting significant anti-leukaemia activity, overcoming ABCG2-mediated topotecan resistance
More description
DCC2042 Ex-tbdps-chc
Novel potent MCT1 inhibitor, exhibiting good single agent anticancer efficacy properties
More description
DCC2041 exosensor 517
Novel Dual-Analyte Fluorescent Chemosensor for Visualizing Neurotransmitter Exocytosis
More description
DCC2040 Exatecan Mesylate Dihydrate
Topoisomerase I inhibitor
More description
DCC2038 Ex-527(r)
Potent and selective SIRT1 inhibitor
More description
DCC2037 Ex4-dnp Conjugate 7
Novel glucagon-like peptide 1 (GLP-1) receptor agonist, displaying significantly elongated half-lives and improved long-acting antidiabetic activity in the presence of endogenous anti-DNP antibodies
More description
DCC2036 Ew-7203
Novel ALK5 inhibitor
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X